Patients with acromegaly who switched from monthly injectable somatostatin receptor ligands (SRLs) to a once-daily oral pill, paltusotine (brand name PALSONIFY), maintained stable IGF-1 levels for two years with no new safety signals, according to data presented at ENDO 2026 in Chicago. The findings, pooled from Phase 3 open-label extensions, validate a nonpeptide small-molecule approach that bypasses gastrointestinal degradation, potentially reshaping the supply chain for acromegaly therapies by reducing reliance on injectable depot formulations.
Market signal
The two-year data from the PATHFNDR-1 extension study show that 93% of participants who completed the randomized period enrolled in the extension, with IGF-1 levels remaining stable at 0.81 times the upper limit of normal at 96 weeks. Pituitary tumor volumes were stable in all patients with available scans at 48 weeks. This durability addresses a key clinical question: whether oral therapy can sustain biochemical control beyond the typical 24- to 36-week trial window. For distributors and clinics, the shift from injectable to oral therapy could reduce cold-chain logistics, injection supplies, and patient training burdens.
Technology breakthrough
Paltusotine is a nonpeptide small molecule designed to selectively activate the somatostatin receptor subtype 2 (SSTR2) with over 4,000-fold selectivity over other subtypes. Unlike injectable SRLs (e.g., octreotide, lanreotide) that require monthly depot injections due to peptide degradation in the gut, paltusotine achieves 69% absolute oral bioavailability with a 30-hour half-life supporting once-daily dosing. This contrasts with Mycapssa (oral octreotide), which uses a permeation enhancer for less than 10% bioavailability and twice-daily dosing. The design proof-of-concept suggests potential for other peptide-hormone targets currently dependent on injections.
Regulatory and channel signals
The FDA granted approval for PALSONIFY on September 25, 2025, with commercial availability starting in October 2025. The European Medicines Agency approved it on April 27, 2026, with initial commercialization planned in Germany and Austria. Regulatory applications are under review in Brazil and Japan. The drug is indicated for adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option, positioning it as both a first-line medical therapy and a switch option for patients stable on injectables.
Sourcing context
For medical aesthetics supply-chain buyers, the emergence of an oral alternative to injectable SRLs signals a potential shift in demand for injection-related consumables (syringes, needles, depot formulations) and cold-chain logistics. Clinics may need to adapt inventory management to include oral formulations, while distributors should monitor regulatory approvals in key markets. The broader pipeline from Crinetics, including a Phase 3 trial for carcinoid syndrome and over 10 disclosed programs in endocrinology, indicates expanding opportunities for oral peptide-replacement therapies.
Source: Read the original report | Published: June 15, 2026